Anti-CD20 CAR therapy (Orna Therapeutics)

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameAnti-CD20 CAR therapy (Orna Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > LNPSmall molecules > Nucleosides and nucleotide derivtives > Circular RNACell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapy

Mechanisms of ActionAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOrna Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesOrna Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A